Overview

• Hims & Hers Q3 revenue grows 49% yr/yr, beating analyst expectations

• Adjusted EBITDA for Q3 increases 53% yr/yr, reflecting strong operational execution

• Company in talks with Novo Nordisk to offer Wegovy injections, no agreement yet

Outlook

• Company expects Q4 2025 revenue of $605 mln to $625 mln

• Hims & Hers narrows full-year 2025 revenue guidance to $2.335 bln to $2.355 bln

• Company anticipates full-year 2025 adjusted EBITDA of $307 mln to $317 mln

Result Drivers

• SUBSCRIBER GROWTH - Subscriber base increased by 21% yr/yr, contributing to revenue growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 10 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy."

• Wall Street's median 12-month price target for Hims & Hers Health Inc is $48.00, about 5.3% above its October 31 closing price of $45.46

• The stock recently traded at 60 times the next 12-month earnings vs. a P/E of 80 three months ago

Press Release: ID:nBw8x1gkta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)